Compare · ALB vs CDXS
ALB vs CDXS
Side-by-side comparison of Albemarle Corporation (ALB) and Codexis Inc. (CDXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALB and CDXS operate in Major Chemicals (Industrials), so they compete in similar markets.
- ALB is the larger of the two at $14.24B, about 70.0x CDXS ($203.6M).
- Over the past year, ALB is up 56.3% and CDXS is down 21.5% - ALB leads by 77.8 points.
- ALB has hit the wire 10 times in the past 4 weeks while CDXS has been quiet.
- ALB has more recent analyst coverage (25 ratings vs 12 for CDXS).
- Company
- Albemarle Corporation
- Codexis Inc.
- Price
- $120.64+1.01%
- $2.23+3.00%
- Market cap
- $14.24B
- $203.6M
- 1M return
- -27.35%
- -10.08%
- 1Y return
- +56.34%
- -21.48%
- Industry
- Major Chemicals
- Major Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2010
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 12
Albemarle Corporation
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine Specialties, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes in the areas of steroid chemistry and vitamins, life sciences, pharmaceutical industry, and other markets. It also provides cesium products for the chemical and pharmaceutical industries; zirconium, barium, and titanium products for pyrotechnical applications; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Bromine Specialties segment offers bromine and bromine-based fire safety solutions; specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals for use in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, water purification, beef and poultry processing, and other industrial applications; and other specialty chemicals, such as tertiary amines, biocides, disinfectants, and sanitizers. The Catalysts segment provides hydroprocessing, isomerization, and akylation catalysts; fluidized catalytic cracking catalysts and additives; and organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, crop protection, and custom chemistry services markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.
Codexis Inc.
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Latest ALB
- Albemarle Corporation to Release Second Quarter 2026 Earnings Results on Wednesday, August 5, 2026
- Director Collins Michelle T was granted 1,252 shares, increasing direct ownership by 385% to 1,577 units (SEC Form 4)
- SEC Form 4 filed by Director Minor Glenda J
- Director Brlas Laurie was granted 1,286 shares, increasing direct ownership by 21% to 7,289 units (SEC Form 4)
- Director Cramer Ralf Hans covered exercise/tax liability with 942 shares and was granted 1,286 shares, increasing direct ownership by 6% to 5,723 units (SEC Form 4)
- Director Wolff Alejandro Daniel was granted 33 shares, increasing direct ownership by 0.25% to 13,044 units (SEC Form 4)
- SEC Form 4 filed by Director Widmar Mark R
- Director Steiner Gerald A was granted 1,286 shares, increasing direct ownership by 11% to 13,232 units (SEC Form 4)
- SEC Form 4 filed by Director Van Deursen Holly
- Director Oconnell Diarmuid B. was granted 1,286 shares, increasing direct ownership by 18% to 8,626 units (SEC Form 4)
Latest CDXS
- SEC Form 8-K filed by Codexis Inc.
- SEC Form 4 filed by Director Parker H Stewart
- SEC Form 4 filed by Director Collins Cynthia
- SEC Form 4 filed by Director Richards Christos
- SEC Form 4 filed by Director Smith David V
- SEC Form 4 filed by Director Singhvi Rahul
- SEC Form 4 filed by Director Martinborough Esther
- SEC Form 4 filed by Director Dilly Stephen George
- SEC Form 4 filed by Director De Vre Raymond
- Director De Vre Raymond sold $6,174 worth of shares (2,605 units at $2.37), decreasing direct ownership by 3% to 84,811 units (SEC Form 4)